Target Upswing

EyePoint, Inc. (NASDAQ:EYPT) received a new price target of $65 from analyst Andreas Argyrides, up from $29, while maintaining a Buy rating. The update highlights a “de‑risked, single‑asset, catalyst‑rich story,” with key Phase 3 readouts for DURAVYU in wet age‑related macular degeneration (AMD) expected in August 2026 and October 2026. The two largest retinal markets—wet AMD and diabetic macular edema—are projected to reach $13 billion in U.S. sales next year, underscoring the commercial upside.